<DOC>
	<DOCNO>NCT02080455</DOCNO>
	<brief_summary>The primary objective study assess effect atorvastatin , weak cytochrome P450 ( CYP ) 3A4 inhibitor , pharmacokinetics ( PK ) lomitapide 2 primary metabolite , M1 M3 .</brief_summary>
	<brief_title>Evaluate Effect Atorvastatin Pharmacokinetics Lomitapide Healthy Subjects .</brief_title>
	<detailed_description>This study single center , randomize , open-label , 2-arm study evaluate effect atorvastatin , weak CYP3A4 inhibitor , PK lomitapide healthy male female subject atorvastatin administer simultaneously lomitapide administer 12 hour lomitapide .</detailed_description>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>1 . Healthy male female , 18 55 year age inclusive 2 . BMI 18.5 32.0 kg/m2 , inclusive ; total body weight &gt; 110 lb ( 50 kg ) ; 3. good health , determine clinically significant relevant abnormality identify detailed medical history 4. creatine phosphokinase , AST , ALT level must 1.5 time upper limit normal 5. clinical laboratory evaluation within reference range test laboratory 6. negative test select drug abuse 7. negative hepatitis panel negative HIV antibody screen 8. male either sterile agree use approve method contraception 9. female must negative serum beta human chorionic gonadotropin pregnancy test require use medically acceptable method contraception . 10. able comprehend willing sign Informed Consent Form 1. significant history clinical manifestation metabolic , allergic , dermatological , hepatic , renal , hematological , pulmonary , cardiovascular , GI , neurological , psychiatric disorder 2. history significant hypersensitivity , intolerance , allergy drug compound , food , substance 3. history stomach intestinal surgery resection 4. history Gilbert 's Syndrome suspicion Gilbert 's Syndrome 5. subject abnormality 12lead ECG 6. use drug abuse 6 month prior Checkin ; 7. subject consume 14 unit alcohol per week significant history alcoholism drug/chemical abuse within 1 year prior Checkin 8. use tobacco nicotinecontaining product within 6 month prior Checkin ; 9. participation investigational study drug trial within 30 day prior Checkin ; 10. use prescription medications/products within 14 day prior Checkin unless deem acceptable Investigator Sponsor 11. use overthecounter , nonprescription preparation within 7 day prior Checkin , unless deem acceptable Investigator Sponsor 12. use alcohol , grapefruit ( include star fruit ) , caffeinecontaining food beverage within 72 hour prior Checkin Study Completion 13. poor peripheral venous access ; 14. donation blood ( 500 mL ) 30 day prior Screening Study Completion 15. receipt blood product within 2 month prior Checkin ; 16. acute chronic condition , schedule hospitalization ( inclusive elective surgery study ) schedule travel prior completion study procedure , opinion Investigator , would limit subject 's ability complete and/or participate clinical study ; 17. subject , opinion Investigator , participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>